Mr. Ohno established Pharmit, Inc. in June of 2005 in order to address the unmet medical needs in the field of digestive organ diseases. Prior to this, he has served as researcher on Helicobacter pylori at the School of Medicine, Chiba University for ten years and identified M toxin as a target protein for a new anti-H. pylori drug. He has also worked as a digestive internal medicine doctor specialized in biliary cancer and pancreatic cancer.

Mr. Obase had been Head of The Biological Engineering Research Institute from 2002 to 2005. He graduated from the Department of Science and Engineering at Waseda University in1966. He entered Kyowa Hakko, Ltd, and developed "Allelock" as head of the development team. He was appointed as head of the Institute and manager of the drug development division. He received an award by The Pharmaceutical Society of Japan for his role in the development of Allelock.

Mr. Tanaka entered Kirin Brewery Company, Ltd after graduating from Kyushu University in 1974. He showed powerful leadership during a joint development project with Amgen,Inc as chief technology officer (CTO). Upon completion of the project, he was appointed as CTO in GNI, Inc, and invited to Cell Signals, Ltd. as a board member.

Mr. Namekata started his career as an officer at the Headquarters of the Governor of Tokyo in 1969 after graduating from Hosei University. He founded the Friends Co, public sector firm. The Friends Co carried out various public projects on behalf of the governor's office and established a framework for future drug development in Japan.

早稲田大学法学部卒業
公認会計士資格取得
株式会社ファルミット監査役就任

東北大学薬学部卒業
エーザイ株式会社入社
ファイザー株式会社を経て、リーベンス創業

弘前大学医学部卒業
兵庫医科大学教授
日本へリコバクター学会会長
厚生労働省ヘリコバクターピロリ感染症班長